Treatment of POEMS Syndrome With Daratumumab

Status Completed

Clinical Trial Summary

This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS) syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with the immunomodulatory drug (IMiD) lenalidomide. Objectives of this study include improvement in neuropathy and performance status, as well as improvement in laboratory values and survival.

Clinical Trial Description

This trial investigates the use of DARA, an antibody directed at the human CD38 molecule, for the treatment of patients with POEMS syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with the IMiD lenalidomide. Objectives of this study include improvement in neuropathy and performance status, as well as improvement in laboratory values and survival. Patients will receive DARA in the outpatient setting, with infusions being administered in Infusion 4. Safety and response assessments will occur prior to Cycles 1 through 6, and at the end of DARA treatment. Once DARA is completed, response assessments are completed every 6 months for the first year, then annually until disease progression. Subjects will also be followed for overall survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04396496
Study type	Interventional
Source	University of Arkansas
Contact
Status	Completed
Phase	Phase 2
Start date	September 22, 2020
Completion date	October 16, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06040567` - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Recruiting	`NCT05263817` - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis	Early Phase 1
Active, not recruiting	`NCT02921893` - Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Early Phase 1
Completed	`NCT01816620` - Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	Phase 2
Completed	`NCT02193698` - Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Phase 2
Completed	`NCT01639898` - POEMS Syndrome Treatment With Lenalidomide	Phase 2
Recruiting	`NCT00971685` - The Treatment of Lenalidomide in Patients With POEMS Syndrome	Phase 2
Recruiting	`NCT05476458` - To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope